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I n November 199.?, the International Society forPharmacoeconomics and Outcomes Research
(ISPOR) (then known as APOR) held its first dis-
ease-specific conference on lipid therapy pharrnaco-
economics and outcomes research in Orlando,
Florida. The concept of meeting periodically to
discuss current pharmacoeconornics and outcomes
research for a specific disease or therapeutic state
seemed sound, and after sufficient corporate spon-
sorship was obtained to implement this conference,
we pushed ahead with it. Based on participant feed-
back, this maiden conference exceeded many peo-
ple's expectations in providing practical and scien-
tifically rigorous assessment and exchange of
opinion for current lipid therapy options. Since
much valuable information was presented at the
conference, it was always intended that we would
share conference proceedings with the ISPOR mem-
bership and other interested readers in a. peer-re-
viewed scientific publication, We are theretore very
pleased that the launch of ISPOR's new journal,
Value in Health, allows these proceedings to be
presented in our society's flagship publicati~n,
In this issue of Value in Health we provide the
first group of presentations, which focused ~n cur-
rent clinical understanding and controversies re-
garding cholesterol, lipid therapy, and the ~thero­
sclerosis disease process, This includes the first set
of speaker presentations, a debate, and a reactor
panel discussion. In subsequent issues we will pub-
lish the second group of presentations, which fo-
cused on lipid pharmacoeconomic modeling, and
the third group of presentations focused on using
pharrnacoeconornic analyses in real-world lipid
therapy decision-making.
Reprint requests to: Dr. Joel W. Hay, Department of Phar-
maceutical Economics and Policy, University of Southern
California, CHP-140, 1540 East Alcazar Street, Los Ange-
les, CA 90033.
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Lipids: The Clinical Issues
Cardiovascular disease (CVD) (including stroke),
which claimed the lives of 960,592 Americans in
1995 [l ], remains the leading cause of death in the
United States, Approximately 58 million US adults
(one in five) have known CVD and 14 million have
established coronary artery disease (CAD) [I], Other
industrialized countries experience similar rates of
CVD, and the developing world is seeing a rapid
rate of increase in CVD as infectious diseases are
reduced or eliminated, and Western diet, smoking,
and exercise patterns are increasingly adopted. Car-
diovascular disease is the leading source of health-
care expenditure in both the United States and
most other industrialized countries. The US cost of
cardiovascular diseases and stroke in 1998 is esti-
mated at $274.2 billion [1]. The 5-year cost of cor-
onarv artery disease has been estimated at $50,000
per ~ase [2,3]. Now that proven therapies exist to
reduce CVD through lipid treatments, development
of cost-effective prevention programs to reduce the
mortality as well as the financial burden of CAD
must become national and international priorities.
Recent clinical trials focused on rigorous evalu-
ation of the disease outcomes associated with
lipid-lowering medications, particularly t~e h~­
droxymethylglutaryl coenzyme A reductase inhibi-
tors (statins}, have revolutionized scientific under-
standing of the atherosclerotic disease process, as
well as clinical modalities of treatment. As Dr.
Daniel Rader persuasively shows in the introduc-
tory conference paper, these clinical studies have
created nothing less than a paradigm shift in our
understanding of the atherosclerotic disease pro-
cess [41. Prior to the clinical trials with starin ther-
apies, it was generally assumed by cardiologists
that the primary mechanism for heart attack was a
narrowing of coronary arteries through ather.o-
sclerotic plaques that became increasingly stenotic,
and eventually completely plugged off blood flow.
This view of the atherosclerotic disease process
implied that invasive and expensive surgical revas-
cularization techniques offered the greatest hope
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for patient recovery from disease. Even today in-
terventional cardiology is king, both in terms of
medical community prestige and command over
scarce medical resources.
But the statin trials showed a large and unex-
pected reduction in coronary events, even when
the slowing of progression in stenotic plaques re-
sulting from treatment was unimpressive. Further
investigation showed that, in fact, the majority of
myocardial infarctions (MIs) result from athero-
sclerotic lesions that are only 30-60% stenotic,
and which are often not associated with overt clin-
ical symptoms. The lesions that are often most
harmful are the "vulnerable plaques," that is, un-
stable, with thin fibrous caps.
In these statin clinical trials the medications ap-
pear to stabilize the vulnerable plaques, reducing
their likelihood of dangerous or fatal rupture.
This is highly relevant to clinical practice since, in
contrast to surgical revascularization techniques,
treatment with certain statin agents has been
shown to reduce incidence of disease in patients
who have not yet experienced an MI or other
symptoms of CVD. Since one third of CVD pa-
tients initially present with sudden death, preven-
tion of the first manifestation of CVD is of critical
importance in reducing the burden of CVD death
and morbidity.
As outcomes researchers, we can point to this
line of investigation as a clear example of why
clinical trials with hard clinical endpoints are so
vital. Not only do these clinical trials establish the
true efficacy of the medications under study in re-
ducing mortality and morbidity (which are the
things that really matter to patients, families,
health plans, and payers), rather than surrogate
measures of efficacy, such as serum lipid profiles.
They also shed new light-in this case, revolution-
ize-our understanding of the disease process it-
self. In addition to the obvious need to provide a
solid basis for clinical and economic understand-
ing of drug costs, risks, and benefits, outcomes re-
search can beneficially alter scientific understand-
ing of disease and disease treatment.
A landmark epidemiological study in CVD has
been, and continues to be, the Framingham Heart
Study. This observational cohort study of a sample
of residents of Framingham, Massachusetts is now
in its fourth generation and second half-century.
Dr. William Castelli provides a perspective on lip-
ids and their relation to CVD based on his pioneer-
ing research over several decades with the Framing-
ham study [5]. Framingham has provided much of
our current understanding regarding the relative
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importance of cholesterol, smoking, blood pressure,
and other risk factors in predicting individual patient
risk of CVD. Framingham risk equations are still
considered the gold standard for assessing baseline
risk in pharmacoeconomic modeling of various
CVD treatments and population interventions.
A major issue of contention revolves around
whether low density lipoprotein (LDL) is the best
cholesterol indicator to measure when assessing a
patient's future risk of CVD. A corollary issue re-
lates to whether current National Cholesterol Edu-
cation Program (NCEP) guidelines for treatment,
which are heavily focused on measurement of LDL
cholesterol, provide the best guidance for clinical
decisions. Dr. Castelli makes a strong case that high
density lipoprotein (HDL) cholesterol needs to be
carefully considered when assessing individual risk,
and that, in the Framingham Heart Study, the total
cholesterol-to-HDL ratio is more predictive of cor-
onary events than changes in LDL by itself. Dr.
Castelli and others point out that the Framingham
risk equations have better positive predictive value
for indicating who is at risk for CVD than the cur-
rent NCEP treatment guidelines.
It is rather remarkable to note that more out-
comes data exist for cholesterol treatments based
on rigorous randomized placebo-controlled clini-
cal trials than any other class of medications (with
the possible exception of aspirin). At this point,
more than 200,000 patient-years of detailed fol-
low-up data exist from the numerous landmark
clinical trials of statins and other cholesterol medi-
cations. When one contrasts the level of outcomes
evidence available for lipid medications with, say,
antihypertensive medications, or oral antiglycernic
medications, the difference in clinical outcomes
evidence is astonishing.
Dr. Virgil Brown provides a detailed evaluation
of the landmark lipid clinical trials and puts the
key results into perspective for pharrnacoeco-
nomics and outcomes research [6]. What has been
established thus far is very impressive. Therapy
with certain statins has been demonstrated to re-
duce patient mortality, coronary events, stroke,
and other manifestations of CVD in both pri-
mary and secondary prevention. With two of the
most recent clinical trials-the Cholesterol and
Recurrent Events (CARE) study and the Air Force/
Texas Coronary Atherosclerosis Prevention Study
(AFCAPS/TexCAPS)-the proven benefits of sta-
tin treatment have been extended to patients with
substantially lower baseline LDL cholesterolleve!s
than meet the current NCEP guidelines for pri-
mary and secondary prevention of CVD.
Editorial
Benefits of statin therapy have been demon-
strated in patients with a wide diversity in charac-
teristics, including both genders, middle-aged and
older adults (up to age 80), smokers, diabetics, hy-
pertensive patients, and many others. Also, to the
potential benefit of millions at risk, stroke incidence
was demonstrably lower in several of the statin clin-
ical trials, despite the fact that the Framingham
Heart Study and other epidemiological evidence
have not shown a strong link between serum lipids
and stroke risk (again, demonstrating the value of
rigorous outcomes research).
The drama of the conference's first session re-
sulted from a "debate" between Dr. Evan Stein
and Dr. Jim Shepherd as to whether LDL reduc-
tion was the primary (or only) interventional tar-
get and mechanism of action for lipid therapies in
general and for statins in particular [7,81. The im-
plications of this debate are sizable. If LDL reduc-
tion is the overriding issue, then emphasis on the
potency of LDL reduction therapies and strategies
makes the most sense, both in terms of clinical and
economic decision-making. On the other hand, if
statins and other lipid therapies have different
mechanisms of action, and if the different medica-
tions vary in their efficacy along these other mech-
anisms of action, as well as in their LDL reduction
potency, then the situation is more complex. Un-
der the second scenario, detailed outcomes evi-
dence would be needed for each medication before
its effectiveness and cost-effectiveness could be ac-
curately assessed.
Dr. Stein argues that LDL reduction should be
the primary focus of lipid treatment since it is the
only lipid target that has been proven to meet all
the tests of causality as a risk factor for CVD. He
cites an impressive body of evidence from many
different approaches for altering patient serum lip-
ids, ranging from diet, to a variety of medications,
to surgical intervention. The consistent finding in
these studies is that the lowering of LDL choles-
terol through a variety of means is significantly as-
sociated with reducing coronary events, irrespec-
tive of changes in HDL and triglycerides.
Dr. Shepherd takes the opposite view, arguing
that drugs that lower LDL cholesterol have wide-
ranging metabolic effects, and that until we fully
understand both the process of atherogenic pa-
thology and all aspects of each treatment mecha-
nism of action, it is premature to conclude that
treatment effects on LDL alone summarize the
value of any lipid intervention. Dr. Shepherd's evi-
dence to support this position is confined to an
admittedly post hoc analysis of the West of Scot-
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land Coronary Prevention Study (WOSCOPS).
But this landmark clinical trial is a study that he
knows well since he was the WOSCOPS principal
investigator. In WOSCOPS there is evidence of a
"threshold effect" in the relationship between
LDL lowering and coronary event reduction.
WOSCOPS patients treated with pravasratin who
maintained less than 12% reduction in LDL cho-
lesterol had no significant reduction in coronary
events, while patients who achieved at least a 24%
LDL reduction had a maximal benefit of = 45%
reduction in coronary events, irrespective of the
actual level of LDL lowering.
Dr. Shepherd further points out that the pla-
cebo-treated patients in WOSCOPS experienced a
5-year coronary event rate that was close to that
predicted by the Framingham risk equations, after
adjustment for covariate risk factors. The prava-
statin treatment group, on the other hand, experi-
enced a coronary event rate that was only about
half the event rate predicted by the Framingham
risk equations, based on changes in LDL and
other patient risk factors.
What can we make of the conflicting positions
ably presented by Dr. Stein and Dr. Shepherd? As
is often the case, reasonable people can differ in
their conclusions, depending on the amount of
weight that each of them gives to alternative
sources of data and evidence. Few would doubt
Dr. Stein's conclusion that there is a strong body
of evidence that numerous alternative treatments
have been efficacious in lowering coronary events,
and that the common element among all of these
interventions is the reduction of LDL cholesterol
levels. Nevertheless, with the evidence that exists
today, it would be impossible to prove the nega-
tive position that nothing other than LDL matters,
and that each lipid medication, diet, or other
treatment only affects humans through its impact
on reduction in serum LDL cholesterol. There are
drugs that primarily impact non-LDL cholesterol
that have also reduced coronary events in patients
with certain types of lipid disorders, such as gem-
fibrozil in the Helsinki Heart Study [91. It is also
premature to conclude that just because there is
agreement that LDL reduction is causative in re-
ducing coronary heart disease, that all other clini-
cal pathways for impacting the atherosclerotic dis-
ease process are irrelevant, or that there are no
differences across medications in mechanisms of
action.
Dr. Shepherd provides intriguing evidence from
WOSCOPS suggesting that there might be other
things happening to reduce coronary events than
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just changes in LDL cholesterol, but it is impor-
tant to point out that WOSCOPS was a single-
dose study (40 mg pravastatin QD). This study
was never intended to address what is fundamen-
tally a dosing question: do different levels of lipid
medication produce different levels of benefit, and
if so, is the relationship linear, curvilinear, or
something else? Moreover, are there one or more
sharp thresholds of clinical benefit quanta, so that
unless a patient crosses a specific level of LDL re-
duction (e.g., 12 %) the benefits are zero, but once
that threshold is crossed, the benefits jump to a
large level and stay there, irrespective of the level
of additional LDL lowering?
Observing differences in outcomes across
WOSCOPS treatment subgroups by quintile of
LDL lowering was also not a prespecified analysis
of this clinical trial. Shepherd and his WOSCOPS
colleagues have been careful to report only findings
that are robust with respect to choice of study pop-
ulation subgroups and analytic approach. Never-
theless, he admits that this type of post hoc analysis
should be considered as "hypothesis-generating"
rather than conclusive. Moreover, the confidence
intervals around the coronary event risk reductions
by quintile of LDL lowering in WOSCOPS are
wide enough so that many possible alternative rela-
tionships between LDL reduction and coronary
event reduction can be inferred from this dataset.
Where do we go from here to settle this? Our fi-
nal inclusion from the conference in this issue is a
panel discussion of the clinical issues and contro-
versies raised by the five speakers [101. The ques-
tions and responses and audience reactions are
quite informative. In the April 21, 1998 issue of
Circulation there is an excellent summary of the
clinical evidence on the relationship between LDL
lowering and coronary event reduction from sev-
eral statin trials, including WOSCOPS, CARE,
and the Scandinavian Simvastatin Survival Study
(45). Dr. Scott Grundy provides an accompanying
editorial summarizing what is known and how
much remains to be demonstrated [111. It is fair to
say that the issue remains unsettled and will prob-
ably stay that way until additional clinical trials
are conducted involving either head-to-head com-
parisons of medications, or different medication
dosages.
We are pleased that so much valuable and cur-
rent clinical information on lipid therapy was dis-
cussed at the conference and is presented here. Fu-
ture issues of Value in Health will discuss how this
clinical information is utilized by pharmacoecono-
mists to model health outcomes and costs for pa-
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tients and health plans, and how it is used by real-
world decision-makers to make formulary deci-
sions and treatment choices. The clinical controver-
sies and uncertainties certainly do not go away.
They continue to lurk dangerously below the super-
ficial elegance of sophisticated computer models
and slick healthcare and drug product marketing
campaigns.
The informed consumer of pharmacoeconornics
and outcomes information needs to keep focused
on what is actually known about the treatments
under consideration and what is not. The bitter-
sweet news for lipid therapy is that we now have
medications that are proven to save lives and re-
duce cardiovascular disease by 25%, or more, but
many patients are reluctant to use them. Are the
drugs too expensive? Are patients fully informed
about the benefits and risks? Are health plans us-
ing appropriate treatment guidelines to treat pa-
tients? Many would like to know the answers to
these questions.
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